CompaniesTheradex
Theradex logo

Theradex

active
Princeton, NJ, United States
Founded 1982
Website
About

Oncology Clinical Research

Areas of Focus

Categories

Clinical ResearchClinical ResearchClinical ResearchClinical ResearchClinical ResearchNJ, NY, PA
Team (10)
Barry Anderson
Barry Anderson
Barry Anderson, MD, PhD
Theradex
team_member
Hans Rosén
Hans Rosén
Hans Rosén
Theradex
team_member
Jack Welch
Jack Welch
Jack Welch, MD, PhD
Theradex
team_member
Jeanne Schow
Jeanne Schow
Jeanne Schow, MBA
Theradex
team_member
Joachim Gullbo
Joachim Gullbo
Joachim Gullbo, MD, PhD
Theradex
team_member
Judy DeChamplain
Judy DeChamplain
Judy DeChamplain, MS, PMP
Theradex
team_member
View all 10 team members →
Clinical Trials (33)
View all

Total Trials

33

As Lead Sponsor

16

As Collaborator

17

Total Enrollment

1,554

By Phase

PHASE2: 18PHASE1/PHASE2: 7PHASE3: 2PHASE1: 6

By Status

UNKNOWN: 16COMPLETED: 9TERMINATED: 4RECRUITING: 2NOT_YET_RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline33 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
NCT00003160
NCT00003326
NCT00003327
NCT00014547
NCT00025688
NCT00024388
NCT00024414
NCT00024362
NCT00024401
NCT00024375
NCT00039169
NCT00039156
NCT00053105
NCT00069966
NCT00111904
NCT02879669
NCT03008187
NCT05732103
Hover over trial bars to see details

Recent Trials

NCT07033598Lead Sponsor
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
PHASE2Not yet recruiting
66 participants
Started: Dec 31, 2025 · Completed: Dec 31, 2028
NCT05280314Collaborator
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
PHASE2Recruiting
60 participants
Started: Dec 21, 2023 · Completed: Jan 31, 2027
NCT05732103Collaborator
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
PHASE1/PHASE2Recruiting
225 participants
Started: Apr 25, 2023 · Completed: Feb 28, 2029
NCT05077709Collaborator
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
PHASE2Active, not recruiting
63 participants
Started: Feb 14, 2022 · Completed: Nov 30, 2024
NCT04061421Collaborator
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
PHASE1/PHASE2Unknown
105 participants
Started: Dec 10, 2021 · Completed: Aug 31, 2025
View all 33 trials →
Locations (1)
Headquarters
Princeton, NJ, United States
Map

Loading map...